Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Fusie Lymph&Co, 2,6 miljoen euro extra voor wetenschappelijk onderzoek
feb 2018 | Lymfoom